Allvivo Inc.
This article was originally published in Start Up
Executive Summary
Allvivo, one of the newest surface modification companies, is jumping into the hottest and most financeable segment of the medical device industry with its own drug-coated coronary stent. Its biomimetic stent coating has two properties that suit it for its intended use; a polymer coating that prevents the attachment and activation of platelets, fibringoen and other coagulation enzymes at the stent surface, and an anti-inflammatory protein.
You may also be interested in...
Biocoatings: Not Just the Icing on the Cake
The successful commercialization of drug-eluting stents (DES) has done much to pave the way for the biocoating industy. DES not only helped establish a new regulatory body to facilitate device-drug reviews, the FDA Office of Combination Products, they also proved that biocoated devices could take market share from uncoated products, command premium pricing and premium reimbursement.
Who Will Join Us? EU Regulators Seek Feedback On Proposed Clinical Trials Discussion Platform
Regulators want to know who is interested in joining their planned multi-stakeholder platform for discussions on how to improve clinical trials in Europe. They are also seeking feedback on which topics should be prioritized for discussion.
Sandoz Maintains Lead On Denosumab As It Files With FDA
Sandoz has confirmed that its denosumab biosimilar BLA has been accepted for review by the US FDA. The company – which has previously characterized its development program as a frontrunner compared to other proposed Prolia/Xgeva rivals – indicated that it was “among the first” to file.